Table 5 Time to onset of AEs by drug class and route of administration
Adverse event | All patients (N = 1992) | TK/VEGF inhibitor (n = 1752) | mTOR inhibitor (n = 233) | Oral (n = 1674) | IV (n = 318) |
|---|---|---|---|---|---|
Median, days (Q1–Q3) | Median, days (Q1–Q3) | Median, days (Q1–Q3) | Median, days (Q1–Q3) | Median, days (Q1–Q3) | |
Fatigue/asthenia | 72.0 (29.0, 157.0) | 74.0 (28.0, 168.0) | 63.0 (35.5, 119.0) | 74.0 (28.0, 165.0) | 58.5 (29.0, 118.0) |
Hypertension | 72.0 (28.0, 156.0) | 70.0 (28.0, 151.0) | 116.5 (42.0, 240.5) | 72.0 (29.0, 163.0) | 76.5 (11.5, 138.5) |
Diarrhea | 108.0 (45.0, 211.0) | 111.0 (48.5, 215.5) | 46.0 (25.0, 194.0) | 110.0 (48.0, 214.0) | 46.5 (21.5, 194.5) |
Hand-foot syndrome | 93.5 (43.0, 218.0) | 109.0 (54.0, 231.5.0) | 30.0 (20.5, 53.0) | 112.0 (57.0, 241.0) | 30.0 (10.0, 33.0) |
Dyspnea | 88.0 (28.0, 210.0) | 94.0 (29.0, 227.0) | 68.5 (23.0, 156.0) | 95.0 (31.0, 226.0) | 52.0 (20.0, 146.0) |
Nausea/vomiting | 21.0 (4.0, 78.0) | 27.0 (7.0, 89.0) | 0 | 28.0 (8.0, 90.0) | 0 |
Back pain | 90.0 (31.0, 198.0) | 90.5 (34.0, 197.50) | 89.0 (22.0, 287.0) | 93.0 (34.0, 198.0) | 75.0 (20.0, 196.0) |
Pain in extremity/limb discomfort | 112.0 (46.0, 238.0) | 113.0 (44.0, 238.0) | 95.0 (48.0, 240.0) | 113.0 (46.5, 246.0) | 83.0 (44.0, 165.0) |
Abdominal pain | 98.5 (35.0, 226.5) | 104.5 (36.0, 229.0) | 87.0 (32.5, 195.0) | 104.5 (37.0, 229.0) | 63.5 (30.0, 176.0) |
Anemia | 85.0 (32.5, 183.5) | 93.0 (35.0, 200.0) | 66.0 (26.0, 132.0) | 93.5 (35.0, 201.0) | 64.5 (18.0, 118.0) |
Hypophosphatemia | 100.0 (56.0, 138.0) | 102.0 (60.0, 136.5) | 299.0 (43.0, 498.0) | 110.0 (60.0, 146.0) | 43.0 (9.0, 104.0) |
Neutropenia | 110.0 (47.5, 242.5) | 117.0 (48.0, 245.0) | 37.5 (19.0, 56.0) | 115.0 (48.0, 240.0) | 56.0 (19.0, 465.0) |
Lymphopenia | 108.0 (95.0, 136.0) | 95.0 (95.0, 95.0) | 122.0 (108.0, 136.0) | 115.5 (95.0, 136.0) | 108.0 (108.0, 108.0) |
Hypotension | 105.0 (42.0, 222.0) | 117.5 (44.0, 239.0) | 58.0 (51.0, 179.0) | 111.0 (43.0, 230.0) | 56.0 (41.0, 191.0) |
Proteinuria | 80.5 (29.0, 245.0) | 84.0 (30.0, 235.0) | 56.0 (26.0, 257.0) | 108.0 (41.0, 336.0) | 30.0 (20.0, 84.0) |
Thrombocytopenia | 97.0 (50.0, 188.0) | 93.5 (48.5, 194.0) | 112.0 (52.0, 140.0) | 87.0 (48.5, 187.0) | 140.0 (112.0, 256.0) |
Hepatitis | 154.0 (71.0, 256.0) | 148.0 (71.0, 253.0) | 209.0 (128.0, 326.0) | 150.5 (71.0, 256.0) | 190.0 (166.0, 234.0) |
Thyroid disorders | 133.0 (75.0, 256.0) | 134.0 (79.0, 259.0) | 91.0 (55.0, 196.0) | 133.5 (79.0, 259.0) | 131.0 (62.0, 175.0) |
Renal insufficiency | 94.0 (33.0, 217.0) | 95.0 (39.5, 225.5) | 90.5 (18.0, 62.5) | 97.0 (41.0, 231.0) | 61.0 (14.0, 133.0) |
Adrenal insufficiency | 119.0 (69.0, 213.0) | 108.0 (67.0, 227.0) | 147.0 (118.0, 200.0) | 110.0 (70.0, 218.0) | 132.0 (4.0, 201.0) |
Pneumonitis | 83.0 (29.0, 209.0) | 87.0 (31.0, 223.0) | 73.5 (21.5, 155.5) | 90.0 (31.0, 223.0) | 68.5 (19.5, 150.5) |
Colitis | 97.0 (43.0, 139.0) | 101.5 (66.0, 139.0) | 0 | 106.0 (97.0, 139.0) | 21.5 (0.0, 43.0) |
Guillain-Barré syndrome | 52.0 (52.0, 52.0) | 52.0 (52.0, 52.0) | 0 | 52.0 (52.0, 52.0) | 0 |
Meningoencephalitis | 122.0 (75.0, 159.0) | 122.0 (75.0, 159.0) | 0 | 112.0 (75.0, 159.0) | 122.0 (122.0, 122.0 |
Myasthenia gravis | 0 | 0 | 0 | 0 | 0 |
Rash | 79.0 (37.5, 214.0) | 83.0 (44.0, 220.0) | 55.0 (23.0, 149.0) | 82.5 (47.0, 213.0) | 28.0 (10.0, 224.0) |